US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NovaBridge Biosciences

1.59

-0.1000-5.92%

Post-market: 1.620.0300+1.89%19:51 EDT

Volume:252.83K

Turnover:407.19K

Market Cap:184.44M

PE:-2.41

High:1.71

Open:1.70

Low:1.58

Close:1.69

52wk High:6.79

52wk Low:1.46

Shares:116.00M

Float Shares:64.56M

Volume Ratio:1.58

T/O Rate:0.39%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6591

EPS(LYR):-0.9225

ROE:-59.10%

ROA:-34.98%

PB:0.92

PE(LYR):-1.72

Loading ...

Overview Company News Filings

NovaBridge Biosciences’ Hagler named president, chief commercial officer, files Form 3 ownership statement

NovaBridge names Mark Hagler president and chief commercial officer

Press Release: NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value

NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

NovaBridge Biosciences Highlights 2025 Results and Advances Late-Stage Oncology and Ophthalmology Programs

NovaBridge FY25 net loss widens to $88.3 million; revenue posts no revenue

Novabridge Reports Full Year 2025 Financial Results and Provides Business Update

THOMSON REUTERS

Press Release: NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

NovaBridge Biosciences director Conor Chia-hung Yang files initial beneficial ownership statement

NovaBridge Biosciences expected to post a loss of 5 cents a share - Earnings Preview

NovaBridge Biosciences EVP Denny Hsueh Wen Chu Files Initial Beneficial Ownership Statement

NovaBridge Biosciences General Counsel Lin Liwei Lorraine Files Initial Beneficial Ownership Statement

NovaBridge Biosciences CEO and Director Xi-Yong Fu files Form 3 initial beneficial ownership statement

NovaBridge Biosciences director Emmett Cunningham files initial beneficial ownership statement

NovaBridge Biosciences Files Form 3 for SVP of Clinical Development Claire Xu Cong

NovaBridge Biosciences files initial beneficial ownership statement for Global Controller Adeline Yi Zhang

NovaBridge Biosciences Director Au Chun Kwok Alan Files Initial Beneficial Ownership Statement

NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Novabridge Biosciences: FDA Confirmed Givastomig’s Potential Eligibility for an Accelerated Approval Pathway

THOMSON REUTERS

Novabridge Biosciences: Expects to Initiate a Registrational Phase 3 Combination Trial as Early as Q4 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/NBP/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"NovaBridge Biosciences","latestPrice":1.59,"timestamp":1789156800000,"preClose":1.69,"halted":0,"volume":252833,"hourTrading":{"tag":"盘后","latestPrice":1.62,"preClose":1.59,"latestTime":"19:51 EDT","volume":216,"amount":349.42,"timestamp":1789170664750,"change":0.03,"changeRate":0.018868,"amplitude":0.018868},"delay":0,"changeRate":-0.059171597633136015,"floatShares":64563600,"shares":115999216,"eps":-0.6591,"marketStatus":"Market Closed","change":-0.1,"latestTime":"09-11 16:00:00 EDT","open":1.7,"high":1.71,"low":1.58,"amount":407188.6083986,"amplitude":0.076923,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.6591,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":1.69,"preHourTrading":{"tag":"盘前","latestPrice":1.6997,"preClose":1.69,"latestTime":"09:12 EDT","volume":1157,"amount":1945.8296416,"timestamp":1789132322472,"change":0.0097,"changeRate":0.00574,"amplitude":0.017751},"postHourTrading":{"tag":"盘后","latestPrice":1.62,"preClose":1.59,"latestTime":"19:51 EDT","volume":216,"amount":349.42,"timestamp":1789170664750,"change":0.03,"changeRate":0.018868,"amplitude":0.018868},"volumeRatio":1.575022456061781,"impliedVol":0.9503,"impliedVolPercentile":0.4424},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":64563600,"roa":"-34.98%","roe":"-59.10%","lyrEps":-0.922468,"volumeRatio":1.575022456061781,"shares":115999216,"dividePrice":0,"high":1.71,"amplitude":0.076923,"preClose":1.69,"low":1.58,"week52Low":1.46,"pbRate":"0.92","week52High":6.79,"institutionHeld":0,"latestPrice":1.59,"eps":-0.6591,"divideRate":0,"volume":252833,"delay":0,"ttmEps":-0.6591,"open":1.7,"prevYearClose":3.98,"prevWeekClose":1.8,"prevMonthClose":1.82,"prevQuarterClose":1.95,"fiveDayClose":1.8,"twentyDayClose":1.9,"sixtyDayClose":1.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"NBP","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787212800000,"name":null,"time":"Pre-MKt","dateTimestamp":1787198400000,"actualEps":null},{"market":"US","date":"2026-04-07","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1775534400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1759550400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2026-09-11","current":-2.412381,"percent":1,"low":-20.276437,"twenty":-14.425612,"median":-3.53465,"eighty":-2.290977,"high":-1.667648,"avg":-8.236858,"sd":6.09552,"marketCap":196038675},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-14","current":-12.019491,"twenty":-13.114792,"median":-12.278904,"eighty":-12.077138,"marketCap":480659441},{"date":"2025-11-21","current":-12.077138,"twenty":-13.085968,"median":-12.293316,"eighty":-12.077138,"marketCap":482964762},{"date":"2025-11-28","current":-11.068308,"twenty":-13.06291,"median":-12.192433,"eighty":-11.881137,"marketCap":442621643},{"date":"2025-12-05","current":-11.500664,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"marketCap":459911551},{"date":"2025-12-12","current":-11.298898,"twenty":-12.411494,"median":-12.033903,"eighty":-11.287368,"marketCap":451842927},{"date":"2025-12-19","current":-17.342266,"twenty":-12.688201,"median":-12.048315,"eighty":-11.460311,"marketCap":456552482},{"date":"2025-12-26","current":-20.276437,"twenty":-13.287734,"median":-12.077138,"eighty":-11.500664,"marketCap":533797473},{"date":"2026-01-02","current":-17.429853,"twenty":-17.342266,"median":-12.163609,"eighty":-11.512194,"marketCap":458858303},{"date":"2026-01-09","current":-16.597774,"twenty":-17.482405,"median":-12.235668,"eighty":-11.541017,"marketCap":436953007},{"date":"2026-01-16","current":-16.028458,"twenty":-17.394818,"median":-12.365376,"eighty":-11.569841,"marketCap":421965173},{"date":"2026-01-23","current":-17.03571,"twenty":-17.342266,"median":-13.057145,"eighty":-11.587135,"marketCap":448482110},{"date":"2026-01-30","current":-16.116045,"twenty":-17.3773,"median":-13.33097,"eighty":-11.615959,"marketCap":424270994},{"date":"2026-02-06","current":-14.583269,"twenty":-17.342266,"median":-14.495682,"eighty":-11.742783,"marketCap":383919133},{"date":"2026-02-13","current":-14.189126,"twenty":-17.307231,"median":-14.71465,"eighty":-11.823489,"marketCap":373542940},{"date":"2026-02-20","current":-14.539475,"twenty":-17.167091,"median":-14.517578,"eighty":-11.961843,"marketCap":382766222},{"date":"2026-02-27","current":-14.364301,"twenty":-17.03571,"median":-14.408094,"eighty":-12.019491,"marketCap":378154581},{"date":"2026-03-06","current":-15.94087,"twenty":-17.03571,"median":-14.386197,"eighty":-12.048315,"marketCap":419659352},{"date":"2026-03-13","current":-12.875318,"twenty":-16.991917,"median":-14.364301,"eighty":-12.077138,"marketCap":338955631},{"date":"2026-03-20","current":-11.780478,"twenty":-16.948123,"median":-14.316021,"eighty":-12.077138,"marketCap":310132873},{"date":"2026-03-27","current":-11.167368,"twenty":-16.597774,"median":-14.189126,"eighty":-11.788901,"marketCap":293992129},{"date":"2026-04-02","current":-10.773226,"twenty":-16.597774,"median":-14.101539,"eighty":-11.587135,"marketCap":283615936},{"date":"2026-04-10","current":-3.171352,"twenty":-16.387565,"median":-14.057746,"eighty":-11.527134,"marketCap":280157205},{"date":"2026-04-17","current":-3.495376,"twenty":-16.299978,"median":-13.61981,"eighty":-11.287368,"marketCap":308781505},{"date":"2026-04-24","current":-3.23355,"twenty":-16.221149,"median":-13.10038,"eighty":-11.118286,"marketCap":285651804},{"date":"2026-05-01","current":-3.23355,"twenty":-16.203632,"median":-12.875318,"eighty":-11.061844,"marketCap":285651804},{"date":"2026-05-08","current":-2.906268,"twenty":-16.133562,"median":-12.604261,"eighty":-10.634902,"marketCap":256739678},{"date":"2026-05-15","current":-2.513529,"twenty":-16.045975,"median":-12.365376,"eighty":-3.526795,"marketCap":222045127},{"date":"2026-05-22","current":-2.330251,"twenty":-15.993423,"median":-12.293316,"eighty":-3.374936,"marketCap":205854337},{"date":"2026-05-29","current":-2.448072,"twenty":-15.958388,"median":-12.192433,"eighty":-3.235384,"marketCap":216262702},{"date":"2026-06-05","current":-2.356433,"twenty":-15.651833,"median":-12.134786,"eighty":-3.190946,"marketCap":208167307},{"date":"2026-06-12","current":-1.92442,"twenty":-15.393451,"median":-12.062727,"eighty":-3.136675,"marketCap":170003300},{"date":"2026-06-18","current":-2.055333,"twenty":-15.340898,"median":-11.990667,"eighty":-3.100019,"marketCap":181568151},{"date":"2026-06-26","current":-2.094607,"twenty":-15.292725,"median":-11.780478,"eighty":-2.890558,"marketCap":185037606},{"date":"2026-07-02","current":-2.605168,"twenty":-15.231414,"median":-11.587135,"eighty":-2.686334,"marketCap":230140522},{"date":"2026-07-10","current":-2.434981,"twenty":-15.178862,"median":-11.559911,"eighty":-2.610404,"marketCap":215106217},{"date":"2026-07-17","current":-2.343342,"twenty":-15.091275,"median":-11.517717,"eighty":-2.516147,"marketCap":207010822},{"date":"2026-07-24","current":-2.317159,"twenty":-15.012446,"median":-11.399781,"eighty":-2.437599,"marketCap":204697852},{"date":"2026-07-31","current":-2.146972,"twenty":-14.977411,"median":-11.226206,"eighty":-2.42189,"marketCap":189663546},{"date":"2026-08-07","current":-2.22552,"twenty":-14.977411,"median":-11.123574,"eighty":-2.356433,"marketCap":196602456},{"date":"2026-08-14","current":-2.487346,"twenty":-14.84603,"median":-11.068308,"eighty":-2.356433,"marketCap":219732157},{"date":"2026-08-21","current":-1.87904,"twenty":-14.583269,"median":-11.035987,"eighty":-2.356433,"marketCap":220888642},{"date":"2026-08-28","current":-1.865003,"twenty":-14.539475,"median":-10.707535,"eighty":-2.330251,"marketCap":219238518},{"date":"2026-09-04","current":-1.776193,"twenty":-14.495682,"median":-10.598051,"eighty":-2.317159,"marketCap":208798588},{"date":"2026-09-11","current":-1.667648,"twenty":-14.425612,"median":-3.53465,"eighty":-2.290977,"marketCap":196038675}],"updateTime":1789288389919},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629802034","title":"NovaBridge Biosciences’ Hagler named president, chief commercial officer, files Form 3 ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629802034","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629802034?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:09","pubTimestamp":1776888599,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences filed an initial Form 3 for Mark Arnold Hagler, president and chief commercial officer, dated April 17, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL62M1ZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629704864","title":"NovaBridge names Mark Hagler president and chief commercial officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2629704864","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629704864?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:08","pubTimestamp":1776856090,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences appointed Mark Hagler as president and chief commercial officer.Hagler previously built commercial strategy for Abraxane in new indications.He also led global launch of a core Afinitor indication.Role adds commercial leadership as NovaBridge advances givastomig toward registrational pivotal studies in first-line gastric cancer.Appointment also supports pre-commercial readiness for VIS-101, a dual VEGF-A x ANG-2 inhibitor program in wet AMD.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL7bgG9l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4585","IE00BN0W2V16.EUR","BK4139","LU0314104364.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","NDAQ","BK4588","NBP","SG9999014013.SGD","LU2210150020.SGD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629104060","title":"Press Release: NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2629104060","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629104060?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:00","pubTimestamp":1776855600,"startTime":"0","endTime":"0","summary":"-- Seasoned Biopharma leader bringing deep commercial experience to shape. and inform corporate strategy, clinical trial design and business. givastomig, a potential first-in-class Claudin 18.2 x 4-1BB bispecific. potential best-in-class, dual VEGF-A x ANG-2 inhibitor for wet AMD. \"Welcoming Mark adds meaningful commercial and operational leadership experience to NovaBridge. This year, NovaBridge has demonstrated strong momentum, with compelling clinical data from our two mid-stage, potential best-in-class/first-in-class programs, givastomig and VIS-101. As we progress towards pivotal studies, Mark's perspective will be instrumental in defining our path forward to maximize the value of our pipeline for shareholders and patients,\" said Fu Wei, Executive Chairman of the Board of NovaBridge.\"Joining NovaBridge at this pivotal time is incredibly exciting. I look forward to partnering with my colleagues as we advance givastomig and VIS-101 to pivotal studies. The pipeline is supported by co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP","BK4232","R","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625494826","title":"NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2625494826","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625494826?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:56","pubTimestamp":1775645760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2026 06:56 ET (10:56 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625961863","title":"NovaBridge Biosciences Highlights 2025 Results and Advances Late-Stage Oncology and Ophthalmology Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625961863","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625961863?lang=en_us&edition=fundamental","pubTime":"2026-04-08 05:21","pubTimestamp":1775596905,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences ( ($NBP) ) has issued an update. On April 7, 2026, NovaBridge Biosciences reported its full-year 2025 results, underscoring ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novabridge-biosciences-highlights-2025-results-and-advances-late-stage-oncology-and-ophthalmology-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novabridge-biosciences-highlights-2025-results-and-advances-late-stage-oncology-and-ophthalmology-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBP","BK4139","SSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625696988","title":"NovaBridge FY25 net loss widens to $88.3 million; revenue posts no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2625696988","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625696988?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:50","pubTimestamp":1775595030,"startTime":"0","endTime":"0","summary":"NovaBridge posted a net loss of USD 88.3 million for fiscal year 2025, widening from USD 22.2 million a year earlier.Revenue was unchanged at no revenue, versus USD 632,000 in 2023.Operating loss widened to USD 94.3 million as research and development expenses more than doubled to USD 62.9 million.Cash and cash equivalents totaled USD 210.6 million at year-end, with net cash used in operating activities of USD 20.6 million.NovaBridge forecast cash, cash equivalents and short-term investments of USD 210.8 million will fund operations into Q4 2028, while highlighting givastomig Phase 2 first-patient enrollment and plans to start a registrational Phase 3 trial as early as Q4 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL2vRNKr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625966041","title":"Novabridge Reports Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2625966041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625966041?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:50","pubTimestamp":1775595001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUARHQZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625969836","title":"Press Release: NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2625969836","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625969836?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:50","pubTimestamp":1775595000,"startTime":"0","endTime":"0","summary":"-- Successful transformation to global biotech platform with two mid-stage. and durable responses with broad CLDN18.2 activity, favorable safety, as. well as potential eligibility for FDA's Accelerated Approval Pathway with. potential initiation of a registrational Phase 3 trial as early as Q4. produced rapid, robust and durable responses in treatment nave. wet-AMD patients, and is poised to begin Phase 2b studies in H2 2026. \"Compelling clinical results from the last quarter have reinforced the class-leading potential for givastomig and VIS-101 and meaningfully de-risked their clinical paths forward. For givastomig, the FDA confirmed potential eligibility for an Accelerated Approval pathway at a productive Type B meeting, following robust potential best-in-class Phase 1b efficacy and favorable overall tolerability results. At the same time, VIS-101 continues to advance in wet AMD following its successful Phase 2a readout showing rapid, robust, durable and potential best-in-class respo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","IE00BMPRXR70.SGD","LU0082616367.USD","LU1989764664.SGD","BK4585","BK4532","AMDW","LU0127658192.USD","LU0274383776.USD","AMDL","AMYY","LU2098885051.SGD","BK4605","BK4534","LU0823421333.USD","LU1316542783.SGD","LU1880398471.USD","LU1861558580.USD","IE0004445239.USD","LU0979878070.USD","LU1880398554.USD","LU1988902786.USD","LU1951200564.SGD","LU2458330169.SGD","LU1242518857.USD","LU2931357623.SGD","AMDG","BK4139","LU0889565833.HKD","LU1852331112.SGD","LU0823421416.USD","BK4529","AMDY","LU0056508442.USD","LU1064131342.USD","LU1242518931.SGD","BK4612","IE0009356076.USD","GFS","BK4512","LU0823434740.USD","AMDD","LU2264538146.SGD","LU2360106780.USD","AMDU","BK4543","LU0081259029.USD","LU0642271901.SGD","LU0823434583.USD","LU1803068979.SGD","LU1861559042.SGD","LU0390134368.USD","BK4575","IE00B5949003.HKD","LU0109392836.USD","DAMD","LU2250418816.HKD","BK4573","BK4566","BK4614","IE00BMPRXN33.USD","BK4141","BK4588","LU0198837287.USD","BK4554","LU1303367103.USD","LU0719512351.SGD","LU1923623000.USD","LU1951198990.SGD","LU2458330243.SGD","LU2054465674.USD","LU2355687059.USD","AMUU","LU2089985449.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624859416","title":"NovaBridge Biosciences director Conor Chia-hung Yang files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624859416","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624859416?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:12","pubTimestamp":1775038347,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences director Conor Chia-hung Yang reported employee share options covering 148,623 ADSs, per an initial beneficial ownership filing dated March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL4cmpmr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623262293","title":"NovaBridge Biosciences  expected to post a loss of 5 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2623262293","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623262293?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:03","pubTimestamp":1774900988,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences  expected to post a loss of5cents a share - Earnings Preview NovaBridge Biosciences NBP.OQ NBP.O is expected to  show no change in quarterly revenue when it reports  results on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL8N40I1WW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622144080","title":"NovaBridge Biosciences EVP Denny Hsueh Wen Chu Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622144080","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622144080?lang=en_us&edition=fundamental","pubTime":"2026-03-25 08:08","pubTimestamp":1774397339,"startTime":"0","endTime":"0","summary":"NovaBridge reported that Chu Denny Hsueh Wen, EVP and Head of Strategic Partnership, filed an initial Form 3 statement of beneficial ownership.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL2SZ0NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620292194","title":"NovaBridge Biosciences General Counsel Lin Liwei Lorraine Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292194","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292194?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:45","pubTimestamp":1773884729,"startTime":"0","endTime":"0","summary":"Lorraine Lin Liwei filed an initial statement of beneficial ownership for NovaBridge Biosciences on 03/18/2026.She is listed as an officer with the title of General Counsel.The filing stated that no securities are beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL73tVz8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620292918","title":"NovaBridge Biosciences CEO and Director Xi-Yong Fu files Form 3 initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292918","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292918?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:44","pubTimestamp":1773884694,"startTime":"0","endTime":"0","summary":"Xi-Yong Fu filed an initial statement of beneficial ownership for NovaBridge Biosciences and is listed as Chief Executive Officer and Director.The filing reported 59,823 ordinary shares beneficially owned directly.It also reported employee share options covering 1.25 million ordinary shares at an exercise price of USD 1.07.Restricted share units covering 1.25 million ordinary shares were also reported.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL5tXpmZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620292538","title":"NovaBridge Biosciences director Emmett Cunningham files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292538","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292538?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:36","pubTimestamp":1773884205,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences reported that Emmett Cunningham filed an initial statement of beneficial ownership as a director. The filing disclosed a 2025 employee share option covering 120,000 shares with an exercise price of USD 3.21. The option has an expiration date of Feb. 17, 2036.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL275g0q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620925802","title":"NovaBridge Biosciences Files Form 3 for SVP of Clinical Development Claire Xu Cong","url":"https://stock-news.laohu8.com/highlight/detail?id=2620925802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620925802?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:36","pubTimestamp":1773884166,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences reported that Claire Xu Cong filed an initial statement of beneficial ownership as an officer. The filing lists her role as Senior Vice President, Clinical Development. Claire Xu Cong reported direct ownership of 288,266 ordinary shares. She also reported employee share options covering 22,900 ADSs at an exercise price of USD 61 and 43,690 ADSs at an exercise price of USD 21.15. The filing also reported restricted share units for 36,716 ADSs and 5,405 ADSs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL3q83cM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620292872","title":"NovaBridge Biosciences files initial beneficial ownership statement for Global Controller Adeline Yi Zhang","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292872","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292872?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:32","pubTimestamp":1773883953,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences reported that Adeline Yi Zhang filed an initial statement of beneficial ownership. Zhang is listed as an officer with the title Global Controller. The filing stated that no securities are beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL1Q8VK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620942702","title":"NovaBridge Biosciences Director Au Chun Kwok Alan Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942702","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620942702?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:25","pubTimestamp":1773883528,"startTime":"0","endTime":"0","summary":"Alan Au Chun Kwok filed a Form 3 initial statement of beneficial ownership for NovaBridge Biosciences on 03/18/2026. The filing identifies Au as a director. Au reported a 2024 employee share option for 114,093 shares with an exercise price of USD 1.22. Au also reported a 2025 employee share option for 34,530 shares with an exercise price of USD 3.86.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL1Wzn3S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620467727","title":"NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620467727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620467727?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:30","pubTimestamp":1773678600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 12:30 ET (16:30 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619546825","title":"Novabridge Biosciences:  FDA Confirmed Givastomig’s Potential Eligibility for an Accelerated Approval Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2619546825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619546825?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:35","pubTimestamp":1773664532,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619346826","title":"Novabridge Biosciences: Expects to Initiate a Registrational Phase 3 Combination Trial as Early as Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619346826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619346826?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:35","pubTimestamp":1773664532,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040K9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":65,"code":"91000000","status":"200"}]}}